Here we report that CD44 binds a chondroitin sulfate (CS) proteoglycan, aggrecan, a major component of cartilage. Soluble CD44-IgG and CD44 ⍣ cells bound to aggrecan from rat chondrosarcoma and bovine cartilage, immobilized on microtiter plates. In both cases, binding was blocked by a neutralizing anti-CD44 mAb or by the pretreatment of aggrecan with chondroitinase, but not hyaluronidase or keratanase, indicating that CD44 binds aggrecan in a manner dependent on CS side chains of aggrecan and that hyaluronic acid is not involved in the binding. Structural analysis showed that glycosaminoglycans of aggrecan from rat chondrosarcoma and bovine articular cartilage consist of mainly CS A and a mixture of CS A and C respectively. When immobilized on microtiter plates, both CS A and C bound CD44-IgG, and the reaction was specifically inhibited by an anti-CD44 mAb. In addition, aggrecan augmented apoptosis in cells expressing CD44-Fas chimeric molecules in synergy with a non-blocking anti-CD44 mAb IRAWB14.4, suggesting that CD44-aggrecan interaction can induce oligomerization of the chimeric molecules. These results suggest that aggrecan interacts with CD44 to mediate cell adhesion and to trigger oligomerization of CD44 molecules, which may lead to intracellular signaling.
Introduction

CD44 is an integral membrane glycoprotein of a polymorphic
Cross-linking of CD44 on synovial cells from rheumatoid arthritis (RA) patients with fragmented HA or treatment of family expressed on a wide variety of cell types, including lymphoid cells, myeloid cells, fibroblasts, epithelial cells and these cells with appropriate anti-CD44 mAb up-regulates the expression of VCAM-1 (19). These facts have suggested that endothelial cells (1) (2) (3) (4) . This molecule has many isoforms that bear a variety of inserts in the membrane-proximal portion.
the interaction between CD44 and its ligands in the arthritic joints may play an important role in the pathogenesis of RA. CD44 binds some extracellular matrix components, such as hyaluronic acid (HA) (5), fibronectin (6) , and collagen types
We have previously reported that CD44 binds a chondroitin sulfate (CS) proteoglycan, serglycin, that is secreted from the I and VI (7) (8) (9) , as well as a secretary granule proteoglycan, serglycin (10) .
mouse T cell line CTLL-2 (10, 20) and that enhances the release of granzyme A from CD44-expressing cytotoxic T CD44 has been reported to play important roles in various immunological events: it mediates the release of tumor cells (10) . Since CD44 interacts with CS side chains of serglycin, we have been trying to determine if CD44 can necrosis factor-α and IL-1β (11), co-stimulates T cell proliferation (12, 13) , mediates lymphocyte rolling along the interact with other CS proteoglycans as well. We have recently found that CD44 interacts with an extracellular endothelium (14), and mediates the migration of activated T cells into inflamed sites (15). Of note is that CD44 is strongly matrix CS proteoglycan, versican, secreted from a renal adenocarcinoma cell line (21) . up-regulated in inflamed synovial tissue (16), and anti-CD44 mAb treatment results in a marked reduction in tissue swelling
As an extension of these studies, we herein examined whether CD44 interacts with aggrecan, a major component and in leukocyte infiltration into arthritic joints in mice (17,18). of the cartilage matrix. Aggrecan is a CS proteoglycan with the glycosaminoglycan-phosphatidylethanolamine mixture was sonicated for 10 min and incubated at 60°C for 2 h. After the a core protein of high mol. wt (~230 kDa) encoded by a single gene. The core protein has two N-terminal globular incubation, sodium cyanoborohydride dissolved in methanol (10 mg/ml, 100 µl) was added and the mixture was incubated domains, G1 and G2, linked by a short segment called the interglobular domain, and most of the keratan sulfate (KS) again at 60°C for 16 h. The reaction mixture was then lyophilized and dissolved in 2 M NaCl in 15% ethanol and spun to remove and CS side chains are attached to an extended segment between G2 and a C-terminal globular domain, G3 (22) . the insoluble material. The sample was precipitated with five equivalent volumes of ethanol, and the precipitate was disIn the course of arthritis, aggrecan is cleaved from the cartilage extracellular matrix by several proteinases, such as solved in 0.2 M NaCl and applied to a TSKgel Phenyl Toyopearl 650M (Tosoh, Tokyo, Japan) column equilibrated with 0.2 M aggrecanases (23, 24) and other matrix metalloproteinases (25) , and released into the synovial fluid.
NaCl. After being eluted from the column with 30% methanol, the lipid-linked glycosaminoglycan was lyophilized and reIn this report, we show that aggrecan interacts with CD44, and that this binding mediates cell adhesion and CD44 dissolved in distilled water before use. clustering, which may play an important role at inflammatory CD44-IgG ELISA sites in vivo, such as in joints that have been damaged by arthritis.
CD44-IgG, which consists of the extracellular domain of human CD44 and the Fc portion of human IgG1, was prepared as described previously (5). Rooster comb HA (100 µg/ml in Methods PBS, 50 µl/well) or aggrecan (1 µg/ml in PBS, 50 µl/well) was applied to the wells of 96-well flat-bottom microtiter plates Cells (MS-8596F; Sumitomo Bakelite, Tokyo, Japan). After A murine thymoma cell line, AKR1, provided by Dr Jayne incubation overnight at 4°C, the wells were filled with PBS Lesley (The Salk Institute, La Jolla, CA), was maintained in containing 3% BSA and incubated for 2 h at room temperature DMEM containing 10% FCS, 10 mM HEPES, 2 mM L-glutamine, to block non-specific binding sites. Glycosaminoglycan-1 mM sodium pyruvate, 1% (v/v) ϫ100 non-essential amino degrading enzymes were used as follows: chondroitinase acids, 100 U/ml penicillin, 100 µg/ml streptomycin and 50 µM ABC (10 mU/ml) in 0.1 M Tris-acetic acid (pH 8.0) was 2-mercaptoethanol (complete medium). AKR1 cells applied to the wells and incubated at 37°C for 30 min. At this expressing murine standard form CD44 (A-CD44WT) or a concentration and reaction time, chondroitinase ABC did not chimeric protein made up of murine standard form CD44 and degrade HA, if at all. Hyaluronidase (40 turbidity reducing the cytoplasmic domain of human Fas (A44/F-4) have been units/ml) in 0.1 M sodium acetate (pH 6.0) was applied to the described previously (26).
wells and incubated at 37°C for 2 h. Both enzymes were used in the presence of 1 mM PMSF. After the enzyme treatment, mAb and reagents human IgG1 or CD44-IgG fusion protein (1 µg/ml) with or without mAb BRIC235 for blocking, control mouse IgG2b Rat anti-mouse CD44 mAb IRAWB14.4 (27) and KM201 (28) were purified by Protein G-Sepharose (Pharmacia Biotech, (20 µg/ml) or 5 mM EDTA was added, and the plate was incubated for 2 h at room temperature. The plates were then Uppsala, Sweden) from hybridoma culture supernatant. Antihuman CD44 mAb BRIC235 (29) was purchased from washed and incubated with alkaline phosphatase-conjugated goat anti-human IgG (American Qualex, San Clemente, CA) International Blood Group Reference Laboratory (Bristol, UK). Rat IgG1,κ was purchased from Zymed (San Francisco, at a final concentration of 0.5 µg/ml and incubated for 1 h at room temperature. After the addition of the BluePhos substrate CA). Mouse IgG2b was purchased from Charles River Pharmservices (Southbridge, MA). Human IgG1, HA purified to the wells, the plates were read with a microplate reader NJ-2300 (Nalge Nunc International, Rochester, NY). Each from rooster comb and bovine aggrecan purified from articular cartilage were purchased from Sigma (St Louis, experiment was run in triplicate. For the competition assay using biotinylated aggrecan, MO). HA purified from human umbilical cord was purchased from ICN (Costa Mesa, CA). Rat aggrecan derived from a CD44-IgG (0.75 µg/ml, 25 µl/well) was applied to the wells of 96-well flat-bottom microtiter plates (3690; Costar, Corning, chondrosarcoma cell line, CS A (chondroitin-4-sulfate), CS C (chondroitin-6-sulfate), chondroitinase ABC from Proteus NY) and the plates were incubated over-night at 4°C. The wells were then filled with 3% BSA in PBS(-) and incubated vulgaris, hyaluronidase from Streptomyces hyalurolyticus, and keratanase from Pseudomonas species were purchased for 2 h at room temperature to block non-specific binding sites. In some wells, mAb BRIC235 (20 µg/ml, 20 µl/well) was from Seikagaku Kogyo (Tokyo, Japan). Alkaline phosphataseconjugated streptavidin was purchased from Promega (Madiapplied and pre-incubated at room temperature for 30 min. Biotinylated bovine aggrecan (0.5 µg/ml, 20 µl/well) was then son, WI). BluePhos phosphatase substrate was purchased from Kirkegaard & Perry (Gaithersburg, MD).
added to the wells with or without various concentrations of unlabeled bovine aggrecan or rooster comb HA, and the Neoglycolipids coupled with glycosaminoglycans were prepared by conjugating glycosaminoglycans to dipalmitoyl plates were incubated at room temperature for 2 h. After washing, alkaline phosphatase-conjugated streptavidin phosphatidylethanolamine, according to the method of Mizuochi et al. (30) with some modifications. Briefly, each (diluted 1:500, 25 µl/wells) was applied to the wells and incubated at room temperature for 1 h. After washing, the glycosaminoglycan was dissolved in distilled water (10 mg/ml, 50 µl), then mixed with dipalmitoyl phosphatidylethanolamine BluePhos substrate was added to the wells and the plates were read with a microplate reader. that was dissolved in chloroform:methanol 1:1 (5 mg/ml, 95 µl);
Neoglycolipids of CS A, CS C, KS and human umbilical cord HA (30 µg/ml, 250 µl/well) were immobilized on microtiter plates by drying at 60°C for 5 h. After blocking with 3% BSA in PBS, a binding assay with CD44-IgG or human IgG1 was performed as described above.
Disaccharide analysis
After the treatment of aggrecan with chondroitinase ABC (100 mU/ml, 37°C overnight), unsaturated disaccharide analysis was carried out according to the method of Sugahara et al. (31, 32) . HPLC analysis was performed with the GULLIVER system (Nippon Bunko Engineering, Tokyo, Japan) on a YMC-Pack PA-03 column (YMC, Wilmington, NC; 4.6 mmϫ250 mm), with a programmed linear gradient elution from 16 to 578 mM NaH 2 PO 4 over 60 min at a flow rate of 1.0 ml/min.
Cell adhesion assay
The cell adhesion assay was performed as described previously (33) . Immobilization of HA or aggrecan on microtiter plates and enzyme treatment of the wells were done as described above. A-CD44WT cells were washed and resuspended in DMEM containing 5 µM 2Ј,7Ј-bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein acetoxymethyl ester (BCECF-AM). After incubation for 40 min at 37°C, the cells were washed with and resuspended in serum-free DMEM. Cells were then stimulated with an anti-CD44 mAb IRAWB14.4 (5 µg/ml, for 30 min at 37°C), which enhances HA binding (27,34). The labeled cells (1ϫ10 5 cells/well) were applied to the microtiter plates and incubated for 30 min in the presence or absence of anti-CD44 mAb. Non-adherent cells were removed by inverting the plate. Adherent cells were solubilized with 1% NP-40 in PBS and the fluorescence intensity of each A-CD44WT or A44/F-4 cells were resuspended in serum-free DMEM containing IRAWB14.4 (5 µg/ml). Cells (1ϫ10 4 /well) were seeded into each well of microtiter plates with or without 25 µg/ml rooster comb HA, rat aggrecan, CS A, CS C or KS both aggrecan from rat chondrosarcoma (rat aggrecan) and and incubated for 7 h in a CO 2 incubator at 37°C in 5% CO 2 .
from bovine articular cartilage (bovine aggrecan) (Fig. 1A) , Apoptosis was detected by Cell Death Detection ELISA Plus whereas control human IgG, L-selectin-IgG or P-selectin-IgG (Roche Digagnostics, Mannheim, Germany). In brief, cells did not (Fig. 1A and data not shown). The binding of CD44-were lysed and the lysates were placed into a streptavidinIgG to aggrecan was independent of the presence of divalent coated plate. A mixture of biotin-labeled anti-histone mAb cations and was specifically inhibited by an anti-human and peroxidase-labeled anti-DNA mAb was then added, and CD44 blocking mAb, BRIC235 (Fig. 1A) . Since BRIC235 also the plate was incubated for 2 h. After washing the wells, 2,2Ј-inhibited the binding of CD44-IgG to HA, this result suggests azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) was added that the link protein homology domain of CD44 interacts with and the plate was read at 405 nm. The value thus obtained aggrecan, which also binds HA. This notion was supported represents the amount of peroxidase-labeled anti-DNA mAb by two lines of observation. First, unlabeled bovine aggrecan bound to the DNA component of the nucleosomes that were inhibited the binding of biotinylated rooster comb HA to released from apoptotic cells.
immobilized CD44-IgG in a dose-dependent manner (data not shown). Second, as shown in Fig. 1(B) , unlabeled rooster Results comb HA inhibited the binding of biotinylated bovine aggrecan CD44 specifically binds aggrecan to CD44-IgG by 50% at a concentration of 100 ng/ml, while unlabeled bovine aggrecan needed~30-40 times higher First, we examined the binding of soluble human CD44-IgG to aggrecan immobilized on plastic plates. CD44-IgG bound concentration to inhibit the binding by 50%. Since the mol. wt of aggrecan and rooster comb HA are in a similar range (35, 36) , this result suggests that the binding affinity of CD44 to aggrecan is lower than that to HA, while CD44 uses the same or overlapping regions to recognize these molecules. inhibited CD44-IgG binding to immobilized aggrecan, whereas hyaluronidase or keratanase had little if any effect (Fig. 2) . The dose of keratanase we used was sufficient to block the binding of the anti-KS mAb to immobilized KS (data Collectively, these results show that CD44 can directly interact not shown). Similarly, hyaluronidase effectively abrogated the with both CS A and CS C chains. binding of CD44 to HA with the dose used in this series of CD44-aggrecan interaction mediates cell adhesion experiments. These results indicate that CD44 recognize the CS side chain on aggrecan.
We next examined whether the interaction of CD44 on the To characterize the CS side chain involved in the recognicell surface with immobilized aggrecan could mediate cell tion by CD44, the two kinds of aggrecan were digested with adhesion. As shown in Fig. 5 , AKR1cells expressing murine chondroitinase ABC and the disaccharides obtained were CD44 bound both immobilized rat aggrecan and HA in a subjected to HPLC analysis. The major digest of rat divalent cation-independent manner, and this binding was aggrecan was eluted at the position of unsaturated 4-sulfated almost completely inhibited by the anti-murine CD44 mAb disaccharides (Fig. 3A) , and the major digest of bovine KM201, which blocks CD44 binding to HA. No binding was aggrecan eluted at the position of unsaturated 6-and 4-observed with CD44 -AKR1 cells (data not shown). CD44 ϩ sulfated disaccharides (Fig. 3B) . These results indicate that cells also bound to bovine cartilage aggrecan, albeit less the glycosaminoglycan chain of aggrecan consists primarily efficiently than to rat chondrosarcoma aggrecan, and the of CS A alone or mixture of CS A and CS C, and that these binding was completely blocked by KM201 (data not CS side chains are recognized by CD44.
shown). Chondroitinase ABC pretreatment of rat aggrecan To verify whether these glycosaminoglycans could directly strongly inhibited cell binding, indicating that CD44 ϩ cells be recognized by CD44, we next prepared neoglycolipids of bind aggrecan in a CS-dependent manner. these glycosaminoglycans and examined binding of CD44.
Aggrecan augments the apoptotic signal mediated by a As shown in Fig. 4(A) , neoglycolipids of CS A, CS C and CD44-Fas chimeric protein HA allowed the binding of soluble CD44-IgG, while the neoglycolipid of KS did not. The binding was inhibited by
To evaluate the functional significance of the CD44-aggrecan BRIC235 but not by an isotype-matched antibody (Fig. 4B) .
interaction, we next performed several functional assays with Although the data are not shown, the efficiency of immobilizawhich signals mediated through CD44 have been successfully detected previously. First, we attempted to detect the release tion was comparable among the glycosaminoglycans used. of cytokines such as MIP-1α and IL-12 from mouse peritoneal exudate cells or mouse alveolar macrophage cell line MH-S upon stimulation via CD44 with HA or aggrecan (37, 38) . However, the cytokine release was detectable subsequent to stimulation with HA but not aggrecan (data not shown). Similarly, the proliferation of mouse spleen cells (39) was observed upon stimulation of the cells with HA but not interaction between CD44 and aggrecan was a death induction assay using cells expressing murine CD44-human Fas chimeric protein (26). In this assay apoptosis was used as a parameter of CD44 oligomerization in cells expressing the chimeric CD44-Fas, subsequent to stimulation of cells via the CD44-derived extracellular domain. As shown in Fig. 6 , the anti-murine CD44 mAb IRAWB14.4 induced apoptosis in CD44-Fas-expressing AKR1 cells (26), which was enhanced by the addition of rat or bovine aggrecan, while the addition of HA and CS had no, or minimal, effect. Since oligomerization of Fas is essential for Fas-mediated apoptotic signals (42), our results suggest that aggrecan can augment apoptosis in cells expressing CD44-Fas chimeric proteins through the oligomerization of these molecules.
Discussion
In this study we report that CD44 binds aggrecan derived sufficient to block CD44-HA interactions. The KS side chains of aggrecan were also apparently uninvolved in the interaction may be explained by the fact that CD44-Fas chimeraexpressing cells do not have sufficient ligand-binding ability with CD44. The binding site of aggrecan on the CD44 molecule appears to overlap with, or at least to be very close to, the without IRAWB14.4 stimulation (data not shown). In this assay, however, a mere oligomerization of CD44-Fas chimeric protein hyaluronate-binding site in the link protein homology domain, since the aggrecan binding to human CD44 was blocked may not to be sufficient to induce apoptosis into cells, since certain mAb cannot induce apoptosis even after further crosswith mAb BRIC235, which can block the binding of hyaluronate by recognizing the epitope 2a in the link protein homology linking with secondary antibody (26). Thus, it seems possible that not only oligomerization of CD44-Fas chimeric protein domain of human CD44 (43) . Similarly, the binding of murine CD44 to aggrecan was blocked with mAb KM201, which can with aggrecan, but also some other factors, e.g. stimulation of specific epitopes in the extracellular domain of CD44, may also block CD44-hyaluronate binding by recognizing an epitope in the link homology domain of mouse CD44. We be involved in apoptosis induction by aggrecan. The reason why CD44-binding glycosaminoglycans, HA, CS A and CS C also demonstrated that the binding of soluble biotinylated aggrecan to immobilized CD44-IgG was inhibited by soluble had very little effect to augment apoptosis in synergy with anti-CD44 mAb could have been due to the extent of sugar unlabeled HA in a dose-dependent manner (Fig. 1b) . These results strongly indicate that the CD44-aggrecan interaction chain clustering, in the absence of core protein, which could affect the extent of CD44-Fas chimera cross-linking. is mediated by the link protein homology domain of CD44 and the CS GAG chain of aggrecan.
Unfortunately we were unable to demonstrate that aggrecan induces cytokine release, cell proliferation, Ca 2ϩ Disaccharide analysis indicated that the CS side chains of rat chondrosarcoma aggrecan are exclusively CS A, and mobilization or CD44 shedding. It is currently unclear whether these negative results were due to the assay conditions we those of bovine cartilage aggrecan are CS A and CS C (Fig. 3) . We have previously reported that CD44 binds a CS used or to inherent characteristics of aggrecan. The signaltransducing activity of CD44-aggrecan interaction should be proteoglycan serglycin, that is modified with either CS A or CS C, or a mixture of both (depending on the cell type), in a examined in more detail in the future, probably by a more direct approach such as the examination of changes in the CS-dependent manner (10, 20) , and that depletion of these CS chains from serglycin results in the loss of binding by tyrosine phosphorylation of Src kinases (50-52), activation of Rho-like GTPases (53) or activation of NF-κB (54), which have CD44. To further investigate whether CD44 can directly interact with the CS A and CS C chains, we used neoglycolipid been reported to take place subsequent to the appropriate ligation of CD44. preparations of these GAG chains and found that CD44-Ig can specifically bind both CS A and CS C (Fig. 4) . Note, CD44 is hardly expressed in normal synovial tissue (16) where aggrecan is selectively localized and hence it is however, that previous attempts to detect the interaction between CD44 and GAG chains in the absence of core unlikely that aggrecan interacts with CD44 in vivo, unless certain pathological responses are initiated in situ, such as protein have yielded conflicting results (5, (44) (45) (46) , and that we ourselves were also unable to detect significant binding the mechanical disruption of the synovial tissue and/or the invasion of CD44 ϩ leukocytes into the synovium, which can of CD44 with CS chains previously (10) . The reason why we could clearly detect binding of CD44 with CS A and CS C in occur in arthritis of various etiologies. Consistent with this premise, aggrecan in the extracellular matrix of cartilage is the present study (Fig. 4) might have been partly due to the fact that we could immobilize these GAG chains more actually degraded in the course of arthritis by aggrecanase-1 (ADAMTS-4) and aggrecanase-2 (ADAMTS-11), which efficiently than in previous studies by attaching a lipid tail to them. According to the fact that CD44 directly binds CS A cleave it at the N-terminal interglobular region between the G1 and G2 domains (23, 24) . As a result, the C-terminal and CS C, we suggest that CD44 should be able to interact with other proteoglycans modified with these CS chains fragment of aggrecan with its CS-rich domain is released from the cartilage matrix and detected in synovial fluid of the in general. In accord with this implication, we recently demonstrated that CD44 also binds another CS proteoglycan, arthritic joint (55-57). A separate study by us indicates that aggrecan is also degraded by another ADAMTS member, versican, bearing at least CS C (21). However, the simple presentation of the appropriate CS chains on proteoglycans ADAMTS-1, which cleaves a site in the CS attachment domain (58) . Therefore, soluble degradation products of aggrecan may not be sufficient to allow binding to CD44. As seen with the selectins (47) (48) (49) , certain properties, such as the extent generated by these enzymes contain CS side chains in any case, and, like the degraded low-mol.-wt HA generated to which the sugar chains are clustered, their numbers, sulfation and other modifications, may also affect the binding.
in the inflamed synovium (19,38), they are potentially active in stimulating CD44 ϩ cells. Concurrently, strong up-regulation The exact requirements for binding need to be investigated further.
of CD44 is observed in infiltrating leukocytes and also in endothelial cells in inflamed synovial tissues (16). Hence, a To examine whether CD44-aggrecan interaction can signal cells, we have employed an apoptosis assay using cells future study should be directed to examine the functional ability of the aggrecan degradation products to interact expressing a CD44-Fas chimeric protein. Our results showed that aggrecan can augment apoptotic cell death in CD44-with CD44, which may promote further understanding of the biological significance of the CD44-aggrecan interaction Fas-expressing cells in synergy with a non-blocking anti-CD44 mAb IRAWB14.4, suggesting that aggrecan induces in vivo.
In summary, we have demonstrated in the present study oligomerization of the chimeric molecules, which may lead to intracellular signaling. Aggrecan alone, without IRAWB14. 4 , that CD44 interacts with aggrecan in a manner dependent on the CS chains of aggrecan. Stimulation of CD44 with could not generate apoptotic signals (data not shown), which 13 Yashiro, Y., Tai, X., Toyo-oka, K., Park, C., Abe, R., Hamaoka, T., aggrecan appears to trigger oligomerization of CD44 
